The above evidence suggests that FER, KL-6, SMRP and IL-6 may provide a serum biomarker profile that can distinguish the progression of fibrotic damage due to inflammatory activity in SARD-ILD, making it possible to optimize therapeutic management with immunosuppressants and/or antifibrotics. The gene discussed is MSLN; the disease is interstitial lung disease.